{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:13Z","timestamp":1790166193636,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T00:00:00Z","timestamp":1408060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T00:00:00Z","timestamp":1408060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.60","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T13:17:11Z","timestamp":1408108631000},"page":"e238-e238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"4","author":[{"given":"J F","family":"Seymour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Haregewoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Dufva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,15]]},"reference":[{"key":"BFbcj201460_CR1","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3109\/10428190903267559","volume":"50","author":"S Cooper","year":"2009","unstructured":"Cooper S, Giles FJ, Savona MR . Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma 2009; 50: 1785\u20131793.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201460_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFbcj201460_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11912-012-0253-9","volume":"14","author":"C Fava","year":"2012","unstructured":"Fava C, Rege-Cambrin G, Saglio G . Chronic myeloid leukemia: state of the art in 2012. Curr Oncol Rep 2012; 14: 379\u2013386.","journal-title":"Curr Oncol Rep"},{"key":"BFbcj201460_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/leu.2012.186","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013; 27: 113\u2013117.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"BFbcj201460_CR5","first-page":"S65","volume":"83","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A . Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann Hematol 2004; 83 (Suppl 1): S65\u2013S66.","journal-title":"Ann Hematol"},{"key":"BFbcj201460_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276\u2013283.","journal-title":"Blood"},{"key":"BFbcj201460_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.pharmthera.2006.02.006","volume":"111","author":"JJ Li","year":"2006","unstructured":"Li JJ, Li SA . Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006; 111: 974\u2013984.","journal-title":"Pharmacol Ther"},{"key":"BFbcj201460_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","volume":"155","author":"SS Farag","year":"2011","unstructured":"Farag SS . The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011; 155: 561\u2013579.","journal-title":"Br J Haematol"},{"key":"BFbcj201460_CR9","doi-asserted-by":"publisher","first-page":"11011","DOI":"10.1073\/pnas.0504952102","volume":"102","author":"TA Carter","year":"2005","unstructured":"Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011\u201311016.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201460_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.canlet.2006.12.004","volume":"251","author":"GM Cheetham","year":"2007","unstructured":"Cheetham GM, Charlton PA, Golec JM, Pollard JR . Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007; 251: 323\u2013329.","journal-title":"Cancer Lett"},{"key":"BFbcj201460_CR11","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1021\/jm8012129","volume":"52","author":"JR Pollard","year":"2009","unstructured":"Pollard JR, Mortimore M . Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009; 52: 2629\u20132651.","journal-title":"J Med Chem"},{"key":"BFbcj201460_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . MK-0457 a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500\u2013502.","journal-title":"Blood"},{"key":"BFbcj201460_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm1003","volume":"10","author":"EA Harrington","year":"2004","unstructured":"Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262\u2013267.","journal-title":"Nat Med"},{"key":"BFbcj201460_CR14","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFbcj201460_CR15","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","volume":"120","author":"J Cortes","year":"2012","unstructured":"Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120: 2573\u20132580.","journal-title":"Blood"},{"key":"BFbcj201460_CR16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075\u20132088.","journal-title":"N Engl J Med"},{"key":"BFbcj201460_CR17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783\u20131796.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"BFbcj201460_CR18","first-page":"18s","volume":"24","author":"EH Rubin","year":"2006","unstructured":"Rubin EH, Shapiro GI, Stein MN, Watson P, Begstrom D, Xiao A et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 2006; 24 (Suppl): 18s (Abstr 3009).","journal-title":"J Clin Oncol"},{"key":"BFbcj201460_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-010-1318-9","volume":"67","author":"AM Traynor","year":"2011","unstructured":"Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67: 305\u2013314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbcj201460_CR20","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/0008-5472.CAN-06-2272","volume":"67","author":"P Briassouli","year":"2007","unstructured":"Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S . Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007; 67: 1689\u20131695.","journal-title":"Cancer Res"},{"key":"BFbcj201460_CR21","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/0008-5472.CAN-04-3981","volume":"65","author":"T Hata","year":"2005","unstructured":"Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899\u20132905.","journal-title":"Cancer Res"},{"key":"BFbcj201460_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/cncr.27801","volume":"119","author":"V Sehdev","year":"2013","unstructured":"Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, El-Rifai W . The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer 2013; 119: 904\u2013914.","journal-title":"Cancer"},{"key":"BFbcj201460_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/sj.bjc.6604083","volume":"97","author":"Y Tao","year":"2007","unstructured":"Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97: 1664\u20131672.","journal-title":"Br J Cancer"},{"key":"BFbcj201460_CR24","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-05-3353","volume":"66","author":"F Gizatullin","year":"2006","unstructured":"Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI . The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668\u20137677.","journal-title":"Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201460","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:51:58Z","timestamp":1672959118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,15]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["BFbcj201460"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.60","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,15]]},"assertion":[{"value":"5 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ER and PW are employees of and may own stock in Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. FJG received a grant from Merck for this study. TH received grants from Novartis, BMS and ARIAD outside the submitted work. JLJ received a grant from Merck outside the submitted work. JCortes received grants and consulting fees from ARIAD, BMS, Novartis, Pfizer and Teva outside the submitted work. JClark is an employee of Incyte Corporation. GM received personal fees from Novartis, Roche, BMS and Pfizer outside the submitted work. DWK received a grant from Novartis during this study, honoraria from Novartis, BMS and ILYANG, and a grant from Pfizer outside the submitted work. JFS, AN, PR, F-XM, ID, AH and CP have no conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}